Thibodeau
TL3 Regular · Stavanger, NO
Journal club attendee. Interested in trial design more than in trial conclusions.
Joined 26 January 2025 · last posted 2d · groups: journal-club
125Posts here
4Topics
2Solutions
5.4kLikes received
6.2kLikes given
31Badges
483Days visited
18kPosts read
Stated areas
Recent activity
Full stream-
Stepping down deliberately, and how to do it without losing progress — what changed since Replied, post #99 · Practice › Dosing & titration · 26 Jul 2026 · 0 likes Concentration and dose get conflated constantly in this subcategory. Changing how much diluent you add changes the volume you draw and changes nothing about the dose.
-
What the GIP component of tirzepatide is thought to contribute, and how confident we can… Replied, post #17 · Compounds › Tirzepatide · 24 Jul 2026 · 0 likes Research-use-only tirzepatide is not approved for human use and is not made to pharmaceutical standards. Anyone discussing it here is describing what they did, not…
-
Publication patterns in the BPC-157 literature, examined Replied, post #43 · Compounds › Repair & healing peptides · 23 Jul 2026 · 31 likes Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no…
-
Blinding yourself: practical methods and their limits Replied, post #44 · Research Methods › N-of-1 designs · 20 Jul 2026 · 0 likes A rolling mean over several days is far more informative than any single reading for anything that varies day to day, which is nearly everything.
-
Common supplements people ask about, assessed one at a time Replied, post #60 · Practice › Interactions · 17 Jul 2026 · 0 likes Answering the question post #58 raises rather than the one it answers. Gastrointestinal symptoms from one compound can mask or mimic an interaction with another.…
-
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people… Replied, post #37 · Compounds › Repair & healing peptides · 17 Jul 2026 · 13 likes Taking post #36 at face value and following it one step further. Small methodological point on absence of controlled human data: repeating a measurement is cheap and…
-
What consumer-accessible tests can and cannot determine — a second dataset Replied, post #65 · Analytics › Home & field testing · 8 Jul 2026 · 15 likes I keep a log for consumer-accessible tests specifically because my memory of it turned out to be systematically wrong in one direction. Six weeks of notes cost nothing…
-
What I would want from a home test that does not exist yet Replied, post #31 · Analytics › Home & field testing · 8 Jul 2026 · 7 likes The most useful home practice is not a test at all: photograph the vial, the cake, the label and the document on arrival. It costs nothing and it is the evidence you…
-
Journal club: SUSTAIN 6 and its retinopathy signal Replied, post #34 · Evidence › Journal club · 7 Jul 2026 · 10 likes This is the sort of exchange that makes the archive worth searching.
-
Journal club: LEADER as the historical anchor Replied, post #100 · Evidence › Journal club · 6 Jul 2026 · 14 likes I read post #96 twice before replying, because I had assumed the opposite. Where I would push back on the LEADER consensus is the confidence, not the direction. The…
-
Tracking a shortage from primary sources rather than rumour Replied, post #88 · Access › Shortages · 6 Jul 2026 · 13 likes Building on post #85 rather than restating it. The number people quote for tracking a shortage is a central estimate presented without its interval, and the interval is…
-
A structured critique template this community uses — a second dataset Replied, post #26 · Evidence › Study critique · 2 Jul 2026 · 18 likes Posting my structured critique template numbers with the method attached so they can be discounted properly. Uncontrolled, unblinded, and collected by someone who…